Citations

Showing 10 of 108083 citations.

Dissecting the Neuropathological Contributors to Rapidly Progressive Dementia
Lazar, Evelyn, Ghayal, Nikhil B , Roemer, Shanu F. , Graff‐Radford, Neill R. , Day, Gregory S. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.067009 Get It

AbstractBackgroundMost series exploring the causes of rapidly progressive dementia (RPD) rely on clinical diagnoses, with limited pathological confirmation. This approach may underestimate the contributions of Alzheimer disease and related dementias to RPD, recognizing challenges associated with extrapolating clinical phenotypes to neuropathological diagnoses. A clearer understanding of the neuropathological causes of RPD is needed to inform the diagnosis and treatment of patients. To meet this need, we determined the neuropathological causes of RPD within the Mayo Clinic neurodegenerative brain bank.MethodPatients with disease duration <4.0 years (symptom‐onset to death due to dementia) were identified within the Mayo Clinic neurodegenerative brain bank (1998‐2020). Available clinical records were reviewed, and details extracted including demographics, family history, dominant symptoms/signs at onset, and common comorbidities (depression, psychoses, sleep disturbance). Neuropathological diagnoses were assigned following standard protocols.Result310/8586 (3.6%) cases met RPD criteria. Relative to typically progressive cases, prion disease most commonly presented as RPD (74%, 32/43), followed by progressive supranuclear palsy/corticobasal degeneration (PSP/CBD: 7.5%, 142/1894), other frontotemporal lobar degeneration (FTLD: 5.7%, 32/561), Lewy body disease (LBD: 4.1%, 49/1202), and Alzheimer disease (AD: 1.8%, 48/2687). Average age‐at‐symptom onset was 69.5±10.4 years. Patients with rapidly progressive AD were older than others (p<0.01), except LBD. Patients with FTLD were younger than others (p<0.05), except prion disease. Average disease duration was 2.9±1.0 years: prion diseases had the most rapid disease course (1.6±1.3 years). Comorbid cerebrovascular disease (25.5%), and clinically symptomatic depression (41.3%), psychoses (37.1%) and sleep disturbances (39.4%) were common across groups. Only psychosis was associated with shorter disease duration (β=‐0.31 years, CI95% [‐0.53, ‐0.082]; controlling for age‐at‐symptom onset).ConclusionRapidly progressive neurodegenerative diseases accounted for 3.6% of cases in this neurodegenerative brain bank. Although prion disease commonly presented as RPD, atypical presentations of more prevalent neurodegenerative diseases accounted for most cases. Atypical (rapidly progressive) variants of typical neurodegenerative diseases warrant consideration in clinical practice.
Investigation of differentially expressed proteins through neurofibrillary tangle maturation in Alzheimer’s disease using NanoString’s GeoMx Digital Spatial Profiler
Wickland, Daniel P. , Lesser, Elizabeth R. , Kachergus, Jennifer M., Graff‐Radford, Neill R. , Thompson, E. Aubrey , Moloney, Christina M. , Liu, Chia‐Chen , Blitterswijk, Marka van , Dickson, Dennis W. , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.066668 Get It

AbstractBackgroundNeurofibrillary tangles are dynamic entities with a lifespan encompassing three maturity levels: intracellular pretangles, intracellular mature tangles, and extracellular ghost tangles. Proteins are suggested to be differentially expressed throughout the tangle lifespan; however, past studies may be limited by spatial expression or number of proteins investigated. We sought to assess differences in protein expression across the tangle lifespan using GeoMxTM Digital Spatial Profiler (DSP) by NanoString, a new technology allowing for spatially derived multiplex investigation.MethodWe used DSP to measure protein expression in hippocampi from Alzheimer’s disease (n=6) and nondemented controls (n=2) using the “Human Neural Cell Profiling Core” and “Alzheimer’s Pathology” module. Regions of interest (ROIs) were classified by the major tangle maturity level recognized by a primary fluorescent conjugated tau antibody. Protein expression was normalized to the geomean of the three housekeeping genes. The tau‐positive segment was specifically analyzed for comparisons. ANOVA was used for group‐wise comparisons and t‐test using the Benjamini‐Yekutieli adjustment for multiple tests was used for pair‐wise comparisons.ResultAs expected, cytoskeletal (e.g., MAP2, Tau) and neuronal (e.g., NeuN) markers generally decreased through the neurofibrillary tangle lifespan (Figure). Markers profiled as neurodegenerative (e.g., amyloid‐β1‐42, APOE, APP) generally increased through tangle maturity levels, except for TDP‐43 which decreased. Interestingly, there was no significant difference in ubiquitin expression. Astrocytic GFAP and S100B expression was significantly increased through each maturity level. Expression of microglial‐specific markers P2RY12 and TMEM119 was significantly elevated in ghost tangles compared to mature tangles. Additional microglial/macrophage markers including Iba‐1 and CD68 were generally increased as neurofibrillary tangles matured. Interestingly, APOE expression remained low in pretangles and mature tangles before dramatically increasing in ghost tangles (Figure).ConclusionOur findings suggest that proteins are differentially expressed throughout the tangle lifespan and the majority followed a monotonically directed pattern. Non‐monotonically directed protein patterns may reflect the death of the neuron during the ghost tangle maturity level. Future studies will test the hypothesis that the microenvironment of the hippocampus is altered with increasing vulnerability to tangle pathology.
Characterizing Amyloid Responsive Microglia in a Cognitively Resilient Patient with Alzheimer’s Disease Neuropathologic Change: A Case Report
Przybelski, Scott A. , Lesnick, Timothy G. , Petersen, Ronald C. , Graff‐Radford, Jonathan , Lee, Eddie B, Reichard, Ross R., Nguyen, Aivi T. , Ramanan, Vijay K. , Knopman, David S. , Jack, Clifford R. , Dickson, Dennis W. , Deerlin, Vivianna M. Van , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.066640 Get It

AbstractBackgroundCognitive resilience, the discrepancy observed in individuals with high Alzheimer’s disease (AD) neuropathology and near‐normal cognition, is a growing area of study, wherein multiple factors are responsible. Currently, the role of the microglial activation in cognitive resilience is unknown. Herein described is a case report characterizing the amyloid responsive microglia (ARM) in an 88‐year‐old male decedent homozygous for APOE E4, clinically cognitively intact, and found to have AD neuropathologic change (ADNC) upon autopsy.MethodThe participant was enrolled in the Mayo Clinic Study of Aging (MCSA) and continuously followed for 14 years from 73‐ to 87‐years‐old, wherein serial MRI and clinical assessments were obtained. An autopsy was performed upon death, and routine neuropathologic sections were taken. Formalin‐fixed, paraffin‐embedded sections were stained with H&E, and single immunohistochemistry was performed using antibodies against tau (AT8), beta‐amyloid (6F3D), alpha‐synuclein (LB509), TDP‐43 (pS409/410), and CD163 (10D6). Digital image analysis was performed on dorsolateral prefrontal cortex sections scanned at 40x (Leica GT450). ARM (CD163% area) and beta‐amyloid (% area) measurements were obtained using QuPath threshold classifiers. Descriptive statistics were performed (Graphpad).ResultThe decedent was an 88‐year‐old male, homozygous for APOE E4, with a history of three cardiovascular and metabolic conditions, and lifelong smoking. His MMSE (average 28/30) and global cognition (average ‐0.51) were relatively stable (Figure 1), with no clinical concerns for cognitive impairment. Cortical thickness was normal (temporal meta‐ROI>3 mm) on four serial MRIs. The participant reported high cognitive, physical activities, and education‐occupation scores (upper quartile for the 70+ population). Neuropathologic evaluation was notable for severe cerebral amyloid angiopathy, high ADNC (A3B3C3), and remote microinfarcts. CD163‐positive ARM were observed in the neocortices and perivascular spaces, and the ARM:beta‐amyloid ratio was 0.26 (Figure 1). This ARM:beta‐amyloid ratio trended upwards (>90th percentile) compared to APOE E4/E4‐matched‐ and age‐matched controls provided from the University of Pennsylvania.ConclusionThis case report demonstrates a cognitively resilient individual with an elevated ARM:amyloid ratio. Conversely, lower ARM ratios were observed in a cognitively impaired cohort, raising the possibility ARM may associate with cognition. ARM may represent a protective and phagocytic population, and further studies correlating microglia, cognition, and putative mechanism are required.
The induction of the mitochondrial morphofunctional pathways improves bioenergetics in Alzheimer Disease
Nguyen, Thi Kim Oanh

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.066250 Get It

AbstractBackgroundAlzheimer Disease (AD) currently has no effective treatments. A consistent failure of recent clinical trials focused on Aβ or pTau protein accumulation necessitates the identification of novel therapeutic targets and strategies. The loss of cellular energetics is considered as an underlying dysfunction in AD. We have identified small molecule compounds that partially inhibit mitochondrial complex I (MCI), blocking neurodegeneration via the induction of multiple neuroprotective mechanisms, including the improvement of cellular energy homeostasis in vitro and in vivo in multiple AD models. Mitochondria are highly motile organelles that respond to physiologic cues through the dynamic properties of mitochondrial networks, which are balanced by the flux of fusion and fission events. This study aims to demonstrate that treatment with partial MCI inhibitors improves cellular energetics and function via modulation of mitochondrial dynamics using multiple models, including neuronal cells generated from human iPSCs derived from ApoE4+ late‐onset AD (LOAD) patients and ApoE3+ controls.MethodChanges in protein expression in response to treatment were assessed using the Western Blot analysis. The investigation of mitochondrial morphology was done using electron microscopy. Flow cytometry was used to measure the translocation of glucose transporters to the cell surface. Cellular energetics was assessed using a Seahorse Extracellular Flux Analyzer. Results were validated in 3xTgAD mice.ResultWe found that the 2D culture of LOAD cultures had accumulation of pTau and a significant reduction in the expression of proteins involved in mitochondrial dynamics and function, including mitochondrial preprotein translocase TIM23, mitochondrial transcription factor A, transcription factor FoxO3, and mitochondrial fusion proteins MFN2 and OPA1. Treatment with partial MCI inhibitors improved mitochondrial dynamics, rescuing the expression of MFN2 and OPA1, neuronal bioenergetics, and mitochondrial morphology. MCI inhibitors increased surface translocation of GLUTs enhancing glucose uptake and utilization, which could be measured in 3xTgAD mice in vivo using translational biomarker FDG‐PET.ConclusionMild stress caused by the application of MCI inhibitors induced mitochondrial fusion, improved energy homeostasis, and enhanced glucose uptake and utilization in vitro and in vivo. These findings could be instrumental for the validation of a novel medicinal approach and the development of biomarkers for therapeutic efficacy.
Gene‐based polygenic score analysis identifies novel immune genes with deleterious variants that associate with Alzheimer’s disease
Reddy, Joseph S. , Wang, Xue , Allen, Mariet , Carrasquillo, Minerva M. , Gregory, Jenkins D., Ertekin‐Taner, Nilüfer , Younkin, Steven G. , Carrasquillo, Minerva M. , Biernacka, Joanna M. , Coombes, Brandon J.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.066231 Get It

AbstractBackgroundIn the Alzheimer’s disease sequencing project (ADSP) whole exome dataset, only the well‐known TREM2.pR47H variant shows genome‐wide significance by conventional single variant analysis. To identify novel AD genes related to TREM2, we used gene‐based polygenic score analysis (PGSA) to evaluate an immune, temporal cortical co‐expression network with 229 genes including TREM2.MethodThe most recent whole exome variant call files from the ADSP (NG00067.v7) were subjected to stringent quality control. Post‐QC samples were divided into discovery (4174 samples sequenced at Broad), test (3299 samples sequenced at WashU), and follow‐up (2273 samples sequenced at Baylor) sets. The pruned variants (r2 < 0.2) with a minor allele count over 20 in each gene were analyzed by Broad/WashU PGSA thereby obtaining P‐values (gPbr.wa) for each gene in WashU samples. To assess significance in independent Baylor samples, cumulative Broad/Baylor PGSA was performed using a novel approach in which variants were stratified by both gene (gPbr.wa) and variant (Broad.P).ResultAfter excluding TREM2, the five variants with gPbr.wa ≤ 0.08 and Broad.P ≤ 0.03 showed significant association in Broad/Baylor PGSA. One of these variants showed no evidence of association with AD in the combined dataset. Polygenic scores for the other four variants, which were in three genes, showed significant association in Baylor samples, and significant, essentially identical association in WashU samples. Polygenic scores for nine additional variants in these genes (0.03> Broad.P ≤ 0.13) also showed significant, essentially identical association in Baylor and WashU samples. The association of these 13 variants with AD was driven primarily by six deleterious, protein‐altering variants with minor allele frequencies less than 1%, but the other 7 variants also contributed.ConclusionUsing gene‐based polygenic score analysis to analyze an immune co‐expression network, we identify three novel immune genes with actionable nonsynonymous and stopgain variants that show significant, replicable association with AD in the most recent release of the ADSP whole exome dataset.
Identification of Novel Modifiers of Tau Aggregation and Pathology using a Proximity Proteomics Approach
Lee, Jannifer H. , Liu, Feilin , Tsai, Chih‐Wei, Carlomagno, Yari , DeTure, Michael , Salemi, Michelle , Cook, Casey , Phinney, Brett S. , Golde, Todd E. , Petrucelli, Leonard , Morderer, Dmytro , Khalil, Bilal , Croft, Cara L. , Dickson, Dennis W. , Rossoll, Wilfried

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.065671 Get It

AbstractBackgroundAlzheimer's disease (AD) and related neurodegenerative diseases are characterized by the accumulation of abnormal protein aggregates. A defining hallmark of AD is the formation of neurofibrillary tangles (NFTs) by aggregation of the microtubule‐associated protein tau into pathological oligomers and fibrils. Although NFTs are believed to play a pivotal role in the disease process, we have a poor understanding of how their formation, toxicity, and spread across brain regions is regulated. Recent data suggest that the seeding behavior of tau is governed by patterns of posttranslational modifications and varying filament structures. Understanding how tau‐associated proteins regulate the oligomerization, pathological accumulation, and seeding of tau in affected neurons and glia is of critical importance for therapy development.MethodTo profile the interactome of tau aggregates, we have established proximity‐dependent biotin‐identification (BioID) as a novel method to identify the composition and proximal molecular environment of insoluble protein aggregates in the context of living brain cells and tissue. Using an in vitro and ex vivo model approach coupled with mass spectrometry, we are generating datasets containing top identified proteins, stratified based on significance and molecular pathway. Once we validate their co‐localization with NFTs in the context of human AD pathology, functional characterization of putative modifiers will be performed to assess their impact on tau‐aggregate and toxicity.ResultTo determine the physiological and aggregate specific interacting partners of tau, we are comparing wild type tau (TauWT) with mutant tau (Tau3xMUT) carrying three tauopathy‐associated mutations (A152T/P301L/S320F) that form hyper‐phosphorylated and thioflavin S‐positive aggregates even in the absence of seeding. The proteomic analysis from our pilot study revealed that significantly changed proteins included candidates involved in RNA processing, as well as protein ubiquitination and proteasome degradation.ConclusionThis study provides novel insights into cellular pathways and molecular mechanisms of neurodegeneration, by identifying in the context of living neurons and brain tissue different functional classes of tau‐associated proteins with relevance for AD pathophysiology. These are expected to include proteins that may mediate the toxic effect of NFTs, facilitate the formation or degradation of pathological tau aggregates, and catalyze posttranslational modifications of tau oligomers and associated proteins.
The systemic disruption of P2rx7 alleviates tau pathology in P301S tau mice via inhibition of extracellular vesicle release
Bueser, Katrina Rae , Ikezu, Seiko , Abdullah, Mohammad, Ruan, Zhi , Ikezu, Tsuneya

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.064257 Get It

AbstractBackgroundP2X purinoceptor 7 (P2RX7), an ATP‐gated cation channel present abundantly in the microglia, induces membrane depolarization and extracellular vesicle (EV) secretion. Previous study demonstrated that administration of GSK1482160, a P2RX7 selective inhibitor, suppressed EVs secretion from murine microglia resulting in accumulation of Tsg101+ intraluminal vesicles (ILVs) in the hippocampus, and restored partial behavioral deficits in P301S tau mice. However, the specificity of GSK1482160 to P2RX7 has never been investigated in P301S tau mice. It is crucial to validate whether P2RX7 is a potential target for alleviating the tauopathy phenotype in P301S tau mice. The purpose of this study is to determine if deletion of P2RX7 is sufficient to recapiturate the therapeutic effect of GSK1482160 in tauopathy mouse model.MethodFours and nine‐months‐old P2RX7‐/‐:P301S and P301S mice were generated for the evaluation of ILV accumulation and tau pathology. Primary microglia and astrocytes from WT (C57BL/6) and P2RX7‐/‐ mice, treated with GSK1482160 and ATP for EV secretion. EVs were isolated from conditioned media via the sequential centrifugation and ultracentrifugation. Finally, EVs were quantified by nanoparticle tracking analysis and exosome specific marker CD9 ELISA. Effects of GSK1482160 on EVs secretion from astrocytes/microglia were also assessed using Western blot with EV specific markers Tsg101 and CD9.ResultExosome specific marker Tsg101, CD9, and tau expression levels were reduced in the hippocampus of nine‐months‐old P2RX7‐/‐:P301S mice compared to P301S mice. No significant difference between the two groups at 4 months of age was observed. Strikingly, primary cultured microglia and astrocytes showed reduction in EV secretion in both ATP stimulated or unstimulated condition from P2RX7‐/‐ group compared to WT group. Additionally, GSK1482160 pretreatment significantly reduced EV secretion from WT astrocytes and microglia, although it had no effects in P2RX7‐/‐ cells. These findings were validated by ELISA of EV marker CD9 and immunoblotting of Tsg101 and flotillin‐1 using isolated EVs.ConclusionResults demonstrate that P2RX7 is primarily responsible for ATP‐induced EV secretion from astrocytes and microglia, and systemic disruption of P2RX7 mimics the effect of GSK1482160 in P301S tau mice, including accumulation of ILVs in microglia and suppression of tau accumulation in the hippocampal regions.
Validation of Mitochondria‐Targeted AD Therapeutics in Human Neuronal Cells
Hasan, Md Fayad , Nguyen, Thi Kim Oanh , Trushina, Eugenia

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.062632 Get It

AbstractBackgroundNeurons and astrocytes were differentiated separately from human induced pluripotent stem cells (HiPSC) derived from Late‐Onset Alzheimer Disease (LOAD) female patients carrying Apolipoprotein E4 (ApoE4) allele. Cells from age and sex matched healthy subject carrying Apolipoprotein E3 allele were used as control. These neuronal, astrocytic, and their co‐cultures were assessed to investigate cell‐specific AD phenotypes (Figure 1). We recently demonstrated that application of a small molecule partial mitochondrial complex I inhibitor CP2 blocked neurodegeneration and cognitive decline in multiple mouse models of AD. However, the demonstration that this novel therapeutic approach is efficacious in human brain cells has not been done. Here, we aimed to validate neuroprotective mechanisms induced by CP2 using patient‐derived neuronal cells form LOAD patient. Outcomes will further support the development of these compounds for clinical application.MethodAxonal trafficking of MitoTracker Red stained mitochondria in neuron‐astrocyte co‐cultures was captured using live confocal imaging. The Seahorse XFe96 flux analyzer was used to evaluate mitochondrial bioenergetics in co‐cultures and pure neuronal or astrocytic cultures. Cell Viability Assays were used to perform H2O2 challenge. Quantitative polymerase chain reaction (qPCR), immunohistochemistry, and western blot were carried out to assess alterations in the expression of relevant genes and protein products.ResultWe have found that LOAD cells have a significant reduction in the percentage of motile mitochondria in axons, increased accumulation of neuronal phosphorylated Tau, and altered bioenergetics in neurons and astrocytes compared to the control cells. qPCR revealed elevated expression of inflammation related genes in LOAD co‐cultures. CP2 treatment at concentrations found therapeutically relevant in vivo in APP/PS1 and 3xTgAD mice improved cellular bioenergetics, rescued mitochondrial motility, and provided neuroprotection against H2O2 induced oxidative stress.ConclusionLOAD HiPSC‐derived neuronal co‐cultures and individual brain cells recapitulate mechanisms associated with LOAD allowing validation of a novel mitochondria‐targeted therapeutics. Our results support previous observation in AD mice and the hypothesis that partial inhibition of mitochondrial complex I activates neuroprotective compensatory mechanisms improving cellular energetics in LOAD human neurons even in the presence of mitochondria with abnormal dynamics and energetics. Further efforts are focused on the determination of a cell‐specific mechanisms of neuroprotection.
Association of DNA methylation from the temporal cortex and cerebellum with AD‐related neuropathology and biochemistry
Oatman, Stephanie R., Allen, Mariet , Quicksall, Zachary , Reddy, Joseph S. , Carrasquillo, Minerva M. , Wang, Xue , Nguyen, Thuy , Martens, Yuka A. , DeTure, Michael , Kanekiyo, Takahisa , Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M. , Liu, Chia‐Chen , Yamazaki, Yu , Heckman, Michael G. , Zhao, Na , Murray, Melissa E. , Dickson, Dennis W. , Bu, Guojun

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.060867 Get It

AbstractBackgroundAlzheimer’s disease (AD) is a progressive neurodegenerative disorder neuropathologically characterized by amyloid‐β (Aβ) plaques and tau neurofibrillary tangles often measured by Thal phase and Braak stage, respectively. Frequently, Aβ also deposits in the brain vasculature with severity categorized by a cerebral amyloid angiopathy (CAA) score. Assessment of these and related endophenotypes can reveal biological insights into the phenotypic variability in AD. We hypothesize that, amongst AD patients, severity of neuropathology and brain levels of AD‐related proteins are influenced by variation in DNA methylation (DNAm), the identification of which may uncover biological pathways for AD pathogenesis. To test this, we performed epigenome‐wide association studies (EWAS) using DNAm from the temporal cortex (TCX) and cerebellum (CER) with AD‐related neuropathology measures (Braak, Thal, and CAA) and brain levels of five proteins (apoE, Aβ40, Aβ42, tau, and p‐tau).MethodsDNAm from autopsy‐confirmed AD cases available through the Mayo Clinic Brain Bank was measured by reduced representation bisulfite sequencing (RRBS) from 471 brain samples, 200 of which had both TCX and CER measures. Bisulfite converted reads were sequenced on the Illumina High Seq4000 and quality filtered. Neuropathology scoring was performed by an experienced neuropathologist. TCX levels of five AD‐related proteins from three fractions (buffer‐soluble, detergent‐soluble, and insoluble) were measured by ELISA (Liu et al. 2020). Individual CpG methylation ratios were tested for association with each neuropathological and biochemical measure using the R package CpGassoc.ResultsWe identified multiple epigenome‐wide significant CpGs unique to each AD‐related measure. Comparisons between the TCX and CER revealed region specific CpG associations. The effects of sex, age at death, APOE genotype, and presence of genetic variants for each significant CpG association were also identified.ConclusionsAlthough all neuropathological and biochemical measures tested reflect core AD pathologies, our results demonstrate unique associations of epigenetic factors with these individual phenotypes, suggesting that their variability may be governed by distinct epigenetic processes. Discovery of DNAm changes that underlie specific neuropathological or biochemical outcomes can enhance our understanding of AD pathophysiology and may lead to the identification of novel gene or pathway targets for the different facets of this complex condition.
Integrative single‐nucleus RNAseq analysis identifies cell‐type‐specific expression perturbations in progressive supranuclear palsy
Min, Yuhao , Wang, Xue , İş, Özkan , Reddy, Joseph S. , Nguyen, Thuy , Chalk, Jessica L , Tutor‐New, Frederick Q, Carrasquillo, Minerva M. , Zhang, Ke , Allen, Mariet , Ertekin‐Taner, Nilüfer , Patel, Tulsi , Crook, Julia E. , Carrasquillo, Minerva M. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.060672 Get It

AbstractBackgroundProgressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by cell‐type‐specific tau lesions in neurons and glia. Using bulk brain RNAseq, we previously identified PSP‐associated genes and co‐expression networks that are enriched with cell‐type marker genes. We extended our work to identify cell‐type‐specific expression perturbations in PSP using a systems approach and in vivo validations in a model system.MethodSingle‐nucleus RNAseq (snRNAseq) was performed using 33 frozen brain temporal cortex (TCX) samples from PSP and control brains. After quality control (QC), integration, and clustering of nuclei, each cluster was annotated for its cell type. We identified differentially expressed genes (DEG) in PSP and further investigated them using an independent bulk RNAseq dataset comprising 408 PSP and control TCX samples for replication and assessing co‐expression patterns. Top DEGs were identified and then validated using external bulk RNAseq datasets from a tau transgenic mouse model. Further, the ability of the validated DEGs to rescue tau‐mediated cellular toxicity was evaluated in a tau transgenic Drosophila model.ResultAfter QC, 30 clusters comprised of 27,284 nuclei were obtained, encompassing two neuronal and six glial cell types. DEGs of each cluster revealed cell‐type‐specific PSP associations. Notably, many of the up‐regulated DEGs in the astroglial clusters were members of the bulk RNAseq co‐expression modules that were also up‐regulated in PSP and enriched with astrocytic markers. There were also consistent findings for the up‐regulated DEGs in the endothelial and microglial clusters, and for down‐regulated DEGs in the oligodendroglial clusters. Subsequently, we prioritized 240 DEGs with congruent cell‐type‐specific perturbations in snRNAseq and bulk RNAseq and validated 29 of those using transgenic mouse model data. Lastly, a significant number of the up‐regulated glial genes, when knocked down in a tau transgenic Drosophila model, led to reduced tau‐mediated cellular toxicity, suggesting novel potential therapeutic avenues.ConclusionPSP brains demonstrated robust cell‐type‐specific gene expression perturbations in the glial cells populations that were validated across different datasets. Importantly, inhibiting the up‐regulated expression perturbations rescued tau‐mediated toxicity in a Drosophila model. Our findings highlight the cell‐type‐specific transcriptome changes in PSP and provide potential therapeutic options for primary tauopathies.